Search

A study conducted by researchers at Mass General Brigham found that approximately 1-in-5 patients experience acne recurrence after taking isotretinoin for severe acne, with females and those who had taken lower cumulative dosages being at higher risk. The study, published in JAMA Dermatology, suggests that dosing regimens could be individualized based on patient goals and preferences, as both lower and higher daily dose regimens can be effective as long as a sufficient cumulative dose is reached. The researchers also found that greater cumulative isotretinoin dose was associated with reduced acne recurrence, but not beyond 220mg/kg. [Extracted from the article]

A recent report from Tshwane University of Technology discusses the misuse of isotretinoin in South Africa, a potent retinoid drug primarily used for severe acne treatment. The research explores the epidemiological trends, motivations, health risks, and sociocultural factors contributing to the abuse of isotretinoin. While the drug remains valuable for acne management, the study emphasizes the need for comprehensive approaches involving healthcare professionals, policymakers, and the public to ensure safe and appropriate use through rational medicine interventions. [Extracted from the article]

A study conducted at Fethi Sekin City Hospital explored the relationship between serum lipid levels, psychiatric symptoms, and suicidal ideation in acne patients undergoing isotretinoin therapy. The research found significant correlations between lipid parameters and suicidal ideation, depression, and anxiety scores. The study suggests that serum lipid levels may serve as indicators of psychiatric side effects in patients on isotretinoin therapy, but further research with larger sample sizes is needed to confirm these findings. [Extracted from the article]

Research from Chongqing Hospital of Traditional Chinese Medicine discusses the successful treatment of Follicular occlusion triad (FOT) using adalimumab combined with isotretinoin. The study also reviews current research progress on biologic therapies for FOT, highlighting the effectiveness of adalimumab and secukinumab. Biologic therapies have significantly improved FOT management for patients who do not respond to conventional treatments, with ongoing advancements expected in this field. [Extracted from the article]

The article discusses a systematic review on the outcomes and adverse effects of isotretinoin in acne treatment conducted by researchers at Cardinal Stefan Wyszynski University in Warsaw. Isotretinoin, a drug used for moderate to severe acne that is unresponsive to other treatments, is highlighted for its effectiveness in preventing physical scarring and psychological impacts associated with severe acne. The review emphasizes the importance of careful patient management due to isotretinoin's teratogenic nature, particularly for women of reproductive age who must use contraception during treatment. The research underscores the drug's inhibitory effect on sebaceous gland activity and proliferation, while cautioning about potential side effects across various body systems. [Extracted from the article]

A clinical trial, NCT06698263, is being conducted to assess the impact of weekly isotretinoin administration on sperm production in men with oligozoospermia. Participants will be randomly assigned to receive either isotretinoin or a placebo, with the primary outcome being changes in sperm production over a 20-week treatment period. The study aims to determine if isotretinoin can stimulate spermatogenesis and improve sperm count in infertile men. [Extracted from the article]

A recent study conducted at the University of Tennessee Health Science Center focused on isotretinoin, a form of Vitamin A used to treat severe acne vulgaris. The research highlighted the unique physical and mental side effects experienced by patients on isotretinoin, emphasizing the importance of patient-provider shared decision-making and open dialogue about side effects during monthly visits. The study recommended that dermatologists should present all treatment options to patients and consider creating a systematic documentation of symptoms to guide treatment plans. [Extracted from the article]

Researchers at Bagcilar Training and Research Hospital conducted a study on nail changes in patients receiving systemic isotretinoin therapy for acne vulgaris. The study included 200 patients, with 100 receiving isotretinoin treatment and 100 receiving topical acne treatment. The research found that isotretinoin increased the risk of nail changes, with onychoschizia being the most common change observed. The study concluded that the risk of developing nail changes was associated with the total cumulative dose of isotretinoin and that the changes were reversible. [Extracted from the article]

Researchers at Universidad Autonoma de Bucaramanga conducted a study on the use of isotretinoin and its potential link to inflammatory bowel disease (IBD). While isotretinoin is effective in treating severe acne, concerns have been raised about its association with IBD. The study found a lack of substantial scientific evidence supporting a causal relationship between isotretinoin use and the development of IBD. For more information, readers can refer to the article "The use of isotretinoin increases the risk of inflammatory bowel disease. A narrative review" published in the Iberoamerican Journal of Medicine. [Extracted from the article]

The article discusses the importance of psychological follow-up in rhinoplasty, specifically focusing on the use of isotretinoin as a skin preparation agent. Research suggests that while isotretinoin has beneficial effects on skin preparation, its continuous use before rhinoplasty may interfere with healing and increase the risk of hematological changes. The decision to use isotretinoin should be individualized, taking into account the surgeon's experience, patient characteristics, and balancing aesthetic benefits with potential risks. A collaborative approach between plastic surgeons, dermatologists, and patients is essential for safe and effective use of isotretinoin in rhinoplasty. [Extracted from the article]

Researchers at University Hospital Basel published a case report on a patient with Acute Promyelocytic Leukemia (APL) who was treated with isotretinoin instead of the standard therapy of all-trans retinoic acid (ATRA) in combination with arsenic trioxide (ATO). Despite a prescription error, the patient achieved stable complete remission, suggesting that isotretinoin could be effective in treating APL. The study highlights the potential of isotretinoin as a treatment option for APL, offering new insights into alternative therapies for this type of leukemia. [Extracted from the article]

A recent report from the University of Colorado Anschutz Medical Campus discusses the findings of a study on acne fulminans (AF), a severe form of inflammatory acne commonly found in adolescents. AF is characterized by painful nodules and plaques that can progress to suppurative, ulcerative, and hemorrhagic lesions. The exact cause of AF is unknown, but it has been linked to certain medications and autoinflammatory syndromes. The most common presentation of AF is seen in adolescents starting isotretinoin therapy. The main treatment for AF is a combination of prednisone and isotretinoin, and early identification and treatment are crucial to minimize symptoms and scarring. Further research is needed to determine optimal management. [Extracted from the article]

A recent study conducted by researchers at the University of Warmia and Mazury in Olsztyn, Poland, aimed to evaluate the impact of lifestyle patterns on the occurrence and severity of adverse events (AEs) in patients with acne undergoing isotretinoin therapy. The study found that lifestyle factors such as physical activity, smoking, and eating habits did not affect the incidence and severity of AEs, indicating the safety of isotretinoin regardless of unhealthy habits. The researchers concluded that isotretinoin remains the most effective drug for acne treatment and should not be abandoned despite the AEs. This research has been peer-reviewed. [Extracted from the article]

A study conducted at the University of Alexandria in Egypt explored the effects of isotretinoin treatment on patients with acne vulgaris. The researchers found that isotretinoin treatment increased the expression of the transcription factor p53 in the skin and sebaceous glands of patients. This upregulation of p53 was associated with changes in gene expression related to the pathogenesis of acne vulgaris. The study suggests that increased p53-FoxO1 signaling caused by isotretinoin treatment may explain both the therapeutic effects and adverse effects of the drug. [Extracted from the article]

A recent study conducted at King Saud University in Saudi Arabia aimed to assess the extent of fetal exposure to isotretinoin, a medication used to treat severe acne, and evaluate adherence to risk minimization measures. The study included a cohort of 6,233 women of childbearing age who had received isotretinoin therapy between 2015 and 2020. The results showed a high incidence of fetal exposure to isotretinoin in Saudi Arabia, surpassing global estimates. The researchers emphasized the need for enhanced interventions and robust risk minimization strategies tailored to the specific challenges faced by the Saudi Arabian population. [Extracted from the article]

A recent case report from Hitit University discusses a rare adverse reaction to isotretinoin, a medication commonly used to treat acne vulgaris. The report describes a 21-year-old woman with acne vulgaris who developed acute eosinophilic pneumonia (AEP) after starting isotretinoin therapy. The patient experienced shortness of breath and lung CT imaging revealed lung infiltration. Isotretinoin therapy was discontinued and oral steroids were initiated, resulting in symptom improvement. The report suggests that hypersensitivity pneumonitis may be a potential complication of isotretinoin administration. [Extracted from the article]

A recent report from Yonsei University College of Dentistry highlights the idiosyncratic reactions associated with isotretinoin therapy, a widely used treatment for severe acne. The review emphasizes the importance of vigilant monitoring and appropriate management due to the potential adverse effects on multiple organ systems and bodily functions. The adverse effects range from psychiatric issues to hematological complications, gastrointestinal disturbances, cardiovascular effects, dermatological manifestations, hepatobiliary issues, ophthalmological changes, and orthopedic concerns. Healthcare professionals prescribing isotretinoin should be aware of these potential reactions and implement monitoring protocols to ensure patient safety and improve the quality of care. [Extracted from the article]

A recent study conducted by Betsi Cadwaladr University Health Board in the United Kingdom examined the effects of isotretinoin, a commonly used treatment for severe acne vulgaris, on lipid levels in patients. The study found that one patient experienced progressively worsening hyperlipidemia while on isotretinoin therapy. Further investigation revealed that the patient had been self-administering anabolic steroids and testosterone, which contributed to the abnormal lipid profile. The researchers concluded that healthcare providers should consider evaluating testosterone levels in patients with unexplained elevated LDL cholesterol and low HDL cholesterol while on isotretinoin treatment. [Extracted from the article]

A recent study conducted by researchers at South Valley University in Qena, Egypt, examined the potential ototoxic effects of oral isotretinoin on the inner ears of acne patients. The study found that there was a significant difference in serum blood lipids, auditory brainstem response (ABR) latencies, and pure-tone audiometry (PTA) thresholds before and after treatment with oral isotretinoin. The researchers concluded that serum blood lipids may serve as a predictor of the adverse effects of oral isotretinoin on the inner ears. This study provides valuable insights into the potential side effects of isotretinoin treatment for acne patients. [Extracted from the article]

A recent study conducted by researchers at Washington University School of Medicine focused on the treatment of acneiform eruptions caused by targeted therapies in the pediatric population. The study found that drugs targeting the mitogen-activated protein kinase pathway can lead to severe cutaneous toxicities, with acneiform eruptions being a common challenge to manage. The researchers examined the use of oral isotretinoin as a treatment option after failure of first-line therapies. Two adolescent patients who developed refractory acneiform eruptions while on trametinib were included in the study, and both patients showed improvement with isotretinoin treatment. The researchers recommend further research on treatment therapies in addition to oral antibiotics due to concerns about their impact on the microbiome. [Extracted from the article]

A study conducted at United Arab Emirates University in Al Ain has found a potential link between the acne medication isotretinoin and the development of sacroiliitis, a condition characterized by inflammation of the sacroiliac joints. The study presented two cases of patients who developed sacroiliitis after starting isotretinoin treatment. The precise mechanisms behind this association are not well understood, but it is believed to involve immunomodulation and the alteration of cytokine balance. Clinicians should be aware of this potential adverse effect when prescribing isotretinoin and monitor patients for musculoskeletal symptoms. Further research is needed to better understand the underlying pathways involved. [Extracted from the article]

A recent study conducted in Jordan examined the knowledge, attitude, and risk perception of oral isotretinoin for acne treatment. The study involved 373 participants who had previously used oral isotretinoin for skin disorders. The findings revealed that there were gaps in monitoring and consultation, indicating partial adherence to oral isotretinoin guidelines. The study emphasized the need for comprehensive education and monitoring strategies in isotretinoin therapy for skin disorders. [Extracted from the article]

A recent study conducted by researchers at Aristotle University of Thessaloniki examined the potential link between isotretinoin, a drug used to treat severe acne, and insulin resistance. The study involved a systematic review and meta-analysis of 15 English-language studies focusing on isotretinoin-treated acne patients. The results showed that there is not a clear association between isotretinoin and insulin resistance, but the drug appears to enhance the serum levels of adiponectin, which is involved in glucose metabolism. This information may be useful for individuals researching the effects of isotretinoin on insulin resistance and related conditions. [Extracted from the article]

A recent study conducted at Brigham and Women's Hospital focused on the use of isotretinoin for acne treatment in transgender and gender-diverse individuals receiving masculinizing hormone therapy. The study found that isotretinoin was effective and well-tolerated in most cases, with 87.3% of patients experiencing improvement in their acne and 47.3% achieving clearance. However, premature treatment discontinuation was common and associated with poorer outcomes. The researchers concluded that further research is needed to optimize dosing and address treatment barriers for this population. [Extracted from the article]

A recent study conducted by researchers at the Department of Dermatology has explored the role of TWEAK (tumor necrosis factor related weak inducer of apoptosis) in acne vulgaris. The study involved 100 acne vulgaris patients and 100 healthy controls, and found that the circulating levels of TWEAK were significantly higher in patients with acne vulgaris compared to healthy volunteers. Additionally, the study found that oral isotretinoin treatment led to a significant decrease in TWEAK levels in acne vulgaris patients. These findings suggest that TWEAK may play a role in the development and severity of acne vulgaris, and that oral isotretinoin may be effective in targeting TWEAK and alleviating the condition. [Extracted from the article]

A study conducted at King Abdullah University Hospital in Irbid, Jordan aimed to evaluate the association between the use of oral isotretinoin and menstrual irregularities in acne patients with previously regular menstrual cycles. The study found that 37.1% of the participants experienced changes in their menstrual cycles while undergoing isotretinoin therapy, with the majority returning to normal within two months post-treatment. The duration of treatment, total accumulative dose, and a family history of polycystic ovary syndrome (PCOS) were identified as significant predictors of menstrual irregularities. This research provides valuable insights into the potential impact of oral isotretinoin on the menstrual cycle. [Extracted from the article]

A recent study conducted by researchers at Sao Paulo State University (UNESP) in Brazil examined the effects of isotretinoin, a medication commonly used among adolescents and young adults, on orthodontic tooth movement (OTM) in rats. The study involved 55 animals divided into different groups that received varying dosages of isotretinoin and underwent OTM for different durations. The results showed that isotretinoin at a dosage of 7.5 mg/kg/day reduced tooth displacement during OTM and also affected certain microtomographic parameters. This research provides valuable insights into the potential influence of isotretinoin on orthodontic treatment outcomes. [Extracted from the article]

A research study conducted at Maharishi Markandeshwar University in Haryana, India, aimed to improve the bioavailability of Isotretinoin, a retinoid analogue used to treat Acne vulgaris. The researchers prepared solid lipid nanoparticles (SLNs) and compared them with commercially available formulations. They found that the drug-to-oil phase ratio and homogenizer speed significantly impacted the particle size and drug release. This study provides insights into enhancing the oral bioavailability of Isotretinoin using SLNs. [Extracted from the article]

A systematic review conducted by researchers at the College of Medicine investigated musculoskeletal complications associated with the use of isotretinoin, an antineoplastic drug. The review analyzed 49 studies, including case reports and case series, which examined musculoskeletal symptoms, diagnostic findings, and treatment approaches related to isotretinoin use. The studies identified symptoms such as lethargy, myalgia, low back pain, arthralgia, tendinopathy, and sacroiliitis. The research concluded that isotretinoin-induced sacroiliitis and diffuse idiopathic skeletal hyperostosis (DISH) were notable musculoskeletal complications, emphasizing the importance of monitoring patients for potential side effects and implementing appropriate interventions. [Extracted from the article]

A patent application titled "Fast Diagnosis And Personalized Treatments For Acne" has been published online, proposing methods for diagnosing and treating acne on an individual level. The methods involve analyzing bacterial DNA obtained from a skin sample to determine the presence of specific strains of bacteria associated with acne. The inventors also suggest the use of a vaccine for the prevention and treatment of acne caused by certain strains of bacteria. The patent application describes various methods and compositions, including vaccines, personalized treatments, probiotics, and phages, that target specific strains of the acne-causing bacterium. The application also provides specific phages and sequences that can be used in the treatment of acne. [Extracted from the article]

A new report from the Mayo Clinic in Rochester, Minnesota presents data on the occurrence of mental health symptoms in adolescents treated with isotretinoin for acne. The study found that while adolescents with a prior psychiatric diagnosis were not more likely to receive a new psychiatric diagnosis during treatment, they did experience more psychiatric symptoms, particularly low mood and mood swings. The researchers recommend close monitoring for adolescents with a psychiatric history who have worsening symptoms or new-onset psychiatric symptoms while taking isotretinoin. The study was supported by the National Institutes of Health. [Extracted from the article]

A study conducted in Haryana, India, focused on the development of a nanoemulsified formulation for topical drug delivery. The researchers used a central composite design and surface response methodology to optimize the formulation. The final formulation contained 22.07% of the oil phase and a surfactant to co-surfactant ratio of 40:60, resulting in a particle size of -280 nm and a maximum percentage permeation of -70%. The study concluded that the optimized formulation improved drug permeation compared to the marketed formulation. This research has been peer-reviewed and published in the Indian Journal of Pharmaceutical Education and Research. [Extracted from the article]

A case report from Prince Sultan Military Medical City in Riyadh, Saudi Arabia, discusses a 23-year-old male who developed acute psychosis and hyperactive psychomotor activity after starting isotretinoin therapy for acne vulgaris. The patient showed improvement with the initiation of antipsychotic and antiepileptic medications. The research suggests that dermatologists should inform patients about potential neuropsychiatric side effects before starting isotretinoin therapy. The mechanism behind isotretinoin-induced psychosis is not well understood, but it may involve alterations in the serotonergic neurotransmitter system. [Extracted from the article]

A patent has been issued to the Board of Trustees of the Leland Stanford Junior University for a method of sensitizing cancer cells to differentiation therapy using a mitochondrial uncoupler called niclosamide ethanolamine. Neuroblastoma, a type of cancer that affects neural crest cells, is the focus of this research. Neuroblastoma is a childhood cancer that often presents with metastasis and can be resistant to retinoic acid therapy. The combination therapy described in the patent involves administering niclosamide ethanolamine along with a retinoic acid to overcome resistance and increase differentiation of the cancer cells. This method has the potential to improve treatment outcomes for neuroblastoma patients. [Extracted from the article]

A recent study conducted by researchers at the Division of Pharmacoepidemiology and Pharmacoeconomics examined the impact of risk evaluation and mitigation strategies (REMS) on clinical practice. The study surveyed physicians who prescribed eight REMS-covered drugs, including medications for multiple myeloma. The results showed that while most physicians found REMS programs to be useful in providing drug safety information and facilitating patient discussions, they also desired more information on the benefits and non-REMS-related risks of these drugs. Additionally, some physicians reported that the safe use requirements of REMS programs sometimes led to delays in medication access. The study suggests that there is a need for better integration of REMS processes into clinical workflows. [Extracted from the article]

A recent report from Tabriz University of Medical Sciences in Iran explores the effects of different solvents on the interactions of Isotretinoin and Tretinoin, two medications derived from vitamin A that are commonly used in dermatology treatments. The study found that specific interactions, such as solvent acidity and solvent basicity, have a greater influence on the medications' function than non-specific interactions like polarity. The researchers used various methods, including density functional theory calculations, to gain a deeper understanding of the experimental results. This research provides valuable insights for pharmacists and chemists working on the development of new medications. [Extracted from the article]

A new report discusses the use of retinoid therapy for neuroblastoma, a type of cancer. Retinoids, which are vitamin A derivatives, have been used in clinical practice for over four decades. Isotretinoin, in particular, has shown promise in improving event-free survival in patients with high-risk neuroblastoma. However, its use for this purpose is considered off-label in the US and EU. To promote the use of isotretinoin in Japan, a clinical research team is planning to launch a clinical trial. The report provides an overview of the history, challenges, and prospects of retinoid therapy for neuroblastoma. [Extracted from the article]

A recent study conducted by researchers from Islamic Azad University in Iran examined the practices and attitudes of general practitioners (GPs) in prescribing Isotretinoin for acne vulgaris in primary care. The study found that only 27.6% of GPs prescribed Isotretinoin, with concerns about liver dysfunction, teratogenic effects, and lack of familiarity with the drug being the main reasons for not prescribing it. The study also revealed that older age and attending dermatological courses were associated with more frequent Isotretinoin administration. The researchers concluded that encouraging GPs to participate in supplementary courses and follow national guidelines could increase the prescription of Isotretinoin. [Extracted from the article]

Lipidio Pharmaceuticals Inc. has been issued a patent for methods of treating non-alcoholic steatohepatitis (NASH), a severe form of non-alcoholic fatty liver disease (NAFLD). The patent focuses on the use of an enzyme called Stearoyl-CoA desaturase-1 (SCD-1) and its role in lipid synthesis within sebaceous glands. It also discusses the potential use of SCD-1 inhibitors in treating dermatologic and cosmetic conditions such as acne, oily skin, and seborrheic dermatitis, as well as obesity and related conditions. The patent claims a specific composition for a topical pharmaceutical treatment that aims to reduce weight and alleviate NASH symptoms without the side effects of current systemic drugs. [Extracted from the article]

International research led by the Translational Synthetic Biology Laboratory at Pompeu Fabra University has successfully engineered a type of skin bacterium, Cutibacterium acnes, to produce and secrete a therapeutic molecule for treating acne. The engineered bacterium has been validated in skin cell lines and in mice. This breakthrough opens up possibilities for engineering non-tractable bacteria to address skin conditions and other diseases using living therapeutics. The research team includes scientists from various institutions. The study was published in Nature Biotechnology. [Extracted from the article]

A clinical trial, NCT06172296, is being conducted to test the effectiveness of adding dinutuximab to standard treatment for children with high-risk neuroblastoma. The trial will evaluate the combination of dinutuximab with chemotherapy, surgery, radiation, and stem cell transplantation. It aims to assess survival rates, response rates, adverse events, and other outcome measures. The trial is set to start in 2024 and is expected to be completed by 2029. This phase III trial aims to determine the effectiveness of adding dinutuximab to induction chemotherapy for the treatment of children with high-risk neuroblastoma. The trial will assess survival rates, response rates, toxicities, and explore biomarkers and markers of minimal residual disease. Various treatments and procedures, including radiation, dinutuximab, and scans, are involved in the study. The study is in Phase 3 and is designed as a randomized intervention. The primary purpose is treatment, and patients are followed up after completing the study treatment. The document provides a list of medications, procedures, and alternative names related to cancer treatment. It also provides a list of drugs, procedures, and alternative names for a clinical trial. The trial, known as ANBL2131, is being conducted by the National Cancer Institute (NCI) and aims to study the treatment of high-risk neuroblastoma in patients up to 30 years old. The trial is investigating various aspects of the disease, including genetics [Extracted from the article]

Researchers from Afyonkarahisar Health Sciences University in Turkey conducted a study to investigate the effects of systemic isotretinoin therapy on semen parameters in patients with varicoceles. The study included 46 men scheduled for isotretinoin therapy for acne vulgaris. The researchers found that after treatment, there was an increase in semen volume, sperm concentration, total sperm count, progressive motility, and vitality, but a deterioration in sperm morphology. These changes were more common in patients with varicoceles. The study concluded that systemic isotretinoin therapy positively affects semen parameters except for sperm morphology. [Extracted from the article]

A study conducted by researchers at Jordan University of Science and Technology evaluated the knowledge and awareness of community pharmacists in Jordan regarding isotretinoin therapy and its dispensing practice. The study found that the majority of pharmacists lacked knowledge about the initial dose of isotretinoin, potential side effects, drug interactions, and contraindications. Additionally, 41.3% of pharmacists dispensed isotretinoin without a prescription, and many were unaware of the appropriate duration of therapy. The study suggests the need for educational programs to improve pharmacists' knowledge and awareness of isotretinoin. [Extracted from the article]